Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

被引：0
|
作者：
Winer, Eric S. [1 ]
Garcia, Jacqueline S. [2 ]
Stone, Richard M. [1 ]
Wadleigh, Martha [1 ]
Luskin, Marlise R. [1 ]
Stahl, Maximilian [3 ]
Chen, Evan C. [1 ]
Leonard, Rebecca [2 ]
Noyes, Alexis [1 ]
Galinsky, Ilene [2 ]
Deshpande, Rashmi [4 ]
Borderies, Pascal [4 ]
O'Neill, Vincent [4 ]
DeAngelo, Daniel J. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Dana Farber Inst, Boston, MA USA
[4] BioXcel Therapeut, New Haven, CT USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186598
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Jabbour, Elias
    BLOOD, 2011, 118 (21) : 1550 - 1550
  • [22] Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee, ST
    Hahn, JS
    Ko, YW
    Min, YH
    BLOOD, 2001, 98 (11) : 215B - 215B
  • [23] Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome
    Roboz, Gail J.
    Khoury, H. Jean
    Jabbour, Elias
    Session, Wilena
    Ritchie, Ellen K.
    Miao, Harry
    Faderl, Stefan
    Zheng, Wei
    Feldman, Eric J.
    Arellano, Martha
    Morrison, J. Gilmour
    Ravandi, Farhad
    LEUKEMIA & LYMPHOMA, 2015, 56 (02) : 395 - 400
  • [24] Treatment with imatinib mesylate in patients with refractory or relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or myeloproliferative disorders (MPD).
    Cortes, JE
    Giles, F
    O'Brien, S
    Talpaz, M
    Thomas, D
    Keating, M
    Garcia-Manero, G
    Faderl, S
    Estey, E
    Letvak, L
    Bochinski, K
    Kantarjian, H
    BLOOD, 2002, 100 (11) : 800A - 800A
  • [25] Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib
    Metzeler, Klaus H.
    Winer, Eric S.
    Platzbecker, Uwe
    Verma, Amit
    DeAngelo, Daniel J.
    Tarantolo, Stefano R.
    Sallman, David A.
    Dugan, James
    Groepper, Stefanie
    Goetze, Katharina S.
    Li, Chia-Cheng
    Zhao, Wanying
    Lane, Maureen
    von Roemeling, Reinhard
    Carlisle, Samantha
    Weigert, Anne
    Boehme, Matthias
    Kubasch, Anne Sophie
    Garcia-Manero, Guillermo
    BLOOD, 2022, 140 : 9048 - 9049
  • [26] Perspectives of Patients With Relapsed and Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome on Patient-Clinician Communication About Prognosis and the Future
    Rao, Vinay
    Linsky, Sarah
    Knobf, M. Tish
    PALLIATIVE MEDICINE REPORTS, 2024, 5 (01): : 53 - 62
  • [27] Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
    Greenberg, PL
    Lee, SJ
    Advani, R
    Tallman, MS
    Sikic, BI
    Letendre, L
    Dugan, K
    Lum, B
    Chin, DL
    Dewald, G
    Paietta, E
    Bennett, JM
    Rowe, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1078 - 1086
  • [28] Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
    Zeidan, Amer M.
    DeAngelo, Daniel J.
    Palmer, Jeanne
    Seet, Christopher S.
    Tallman, Martin S.
    Wei, Xin
    Raymon, Heather
    Sriraman, Priya
    Kopytek, Stephan
    Bewersdorf, Jan Philipp
    Burgess, Michael R.
    Hege, Kristen
    Stock, Wendy
    ANNALS OF HEMATOLOGY, 2022, 101 (03) : 557 - 569
  • [29] Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
    Amer M. Zeidan
    Daniel J. DeAngelo
    Jeanne Palmer
    Christopher S. Seet
    Martin S. Tallman
    Xin Wei
    Heather Raymon
    Priya Sriraman
    Stephan Kopytek
    Jan Philipp Bewersdorf
    Michael R. Burgess
    Kristen Hege
    Wendy Stock
    Annals of Hematology, 2022, 101 : 557 - 569
  • [30] Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Zavras, Phaedon D. D.
    Sinanidis, Ilias
    Tsakiroglou, Panagiotis
    Karantanos, Theodoros
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
12345